Mikhail Murashko, Minister of Healthcare of the Russian Federation, got acquainted with the successes of the Medsintez Plant at a training seminar on healthcare issues

The Medsintez Plant took part in the training seminar Topical Issues of Healthcare, which was held on April 25 at the I.M. Sechenov First Moscow State Medical University. The event was attended by over 500 people – heads of healthcare management bodies headed by the Minister of Healthcare of the Russian Federation Mikhail Murashko.

At the exhibition of leading Russian pharmaceutical manufacturers organized as part of the seminar, genetically engineered and analogue human insulin Rosinsulin, the first Russian follicle-stimulating hormone for treatment of infertility Primapur, and an innovative direct antiviral preparation Triazavirin were presented at the the booth of the Medsintez Plant.

Minister of Healthcare of the Russian Federation Mikhail Murashko visited the booth of the Medsintez Plant, getting acquainted with the current developments and successes of the enterprise.

This year, an important event for the Medsintez Plant was the registration of own analogue human insulin Rosinsulin Glargine (100 IU/ml). Thus, the Plant has launched the production of a full cycle of the entire line of products of genetically engineered human insulin Rosinsulin and analogue insulins – Rosinsulin Aspart R and Rosinsulin Glargine from its own substances. In 2023, the Plant is preparing to release the first Russian insulins for veterinary use.

Over 10,000 children have already been born in Russia due to treating female patients using Primapur, the first Russian follitropin alpha, that the Medsintez Plant has been producing since 2019. Today, the Medsintez Plant, together with the Ural State Medical University (USMU), is developing other preparations used in IVF procedure – these are human chorionic gonadotropin (hCG) and cetrorelix.

In 2022, multicenter clinical trials of Triazavirin in a dose of of 100 mg for the treatment of ARVI in children aged 12–17 were successfully completed. Triazavirin showed a high efficacy and a good safety profile. Currently, an approval is expected for clinical trials in children of the next age group – from 6 to 11 years.

The Medsintez Plant is ready to meet the annual demand for vital insulin and FSH preparations in Russia by 100%, as well as to provide substantial support to the country during epidemics or pandemics of diseases caused by RNA viruses. The Plant is ready to launch its own production of reagents for the creation of pharmaceuticals, which will ensure the replacement of inaccessible imported components on the Russian market.